Brief: Vaxart Announces Topline Data From The Phase 2 Challenge Study Of Its Monovalent Norovirus Vaccine Candidate
06/09/2023 22:58
Sept 6 (Reuters) - Vaxart Inc VXRT.O :
* VAXART ANNOUNCES TOPLINE DATA FROM THE PHASE 2 CHALLENGE
STUDY
OF ITS MONOVALENT NOROVIRUS VACCINE CANDIDATE
* VAXART INC - STUDY MET 5 OF 6 PRIMARY ENDPOINTS
* VAXART INC - VACCINE WAS SAFE AND WELL TOLERATED WITH NO
VACCINE-RELATED SERIOUS ADVERSE EVENTS (SAES)
Source text for Eikon: ID:nGNX1qN6Gl
Further company coverage: VXRT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts